OPERA: perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogel.

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can affect patient health-related quality of life (HRQoL). Appropriate information may improve their adherence to treatment and quality of life. To evaluate the change in patient's perceptions of the level of information at lanreotide (LAN) treatment initiation for GEP-NETs vs after 6 months. OPERA (NCT03562091) was a prospective, longitudinal, noninterventional study. Thirty-one centers in France specialized in the management of patients with NETs. Planned clinical visits at enrollment and end-of-study visits at month 6, with completion of the European Organisation for Research and Treatment of Cancer 25-item Quality of Life Questionnaire-Information Module (QLQ-INFO25) and 30-item Quality of Life Questionnaire-Core. Absolute change in the patient's perception of the information between baseline and month 6, using the relevant domains of the QLQ-INFO25. Endpoints measured at baseline and month 6 for at least 1 of the 3 targeted QLQ-INFO25 dimensions of the primary endpoint. Ninety-three of the 115 patients enrolled completed ≥1 primary endpoint information dimension. Mean (SD) scores for the primary endpoint information dimensions were high at baseline (disease, 63.41 [20.71]; treatment, 58.85 [19.00]; supportive care, 26.53 [24.69]; maximum 100). There were no significant changes between baseline (98.34% CI) and 6 months (disease, -2.84 [-8.69, 3.01; P = .24]; treatment, -4.37 [-11.26, 2.52; P = .13]; supportive care, 0.46 [-6.78, 7.70; P = .88]), and in HRQoL between baseline and 6 months. The lack of change in patient's perceptions of the disease, treatment, and supportive care information provided over the first 6 months of LAN treatment may suggest that physicians provided adequate information at the treatment initiation.

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: [e-mail].

Déclaration de conflit d'intérêts

Conflict of interest: V.H. has been involved in advisory boards and has received remuneration from AAA Pharma, Inc., Ipsen, and Novartis. T.W. has been involved in advisory boards and has received remuneration from AAA Pharma, Inc., Ipsen, Keocyt, Novartis, and Roche. C.D.C. has received travel support and remuneration for lectures and advisory board meetings from AAA Pharma, Inc., Ipsen, Novartis, and Pfizer. R.C. has been involved in advisory boards and has received remuneration from Amgen, Ipsen, Keocyt, Merck, Novartis, and Pfizer. S.D. has been involved in advisory boards and has received remuneration from Ipsen. L.M. has received institutional grants from Sanofi, speaker and consultancy fees from Amgen, Ipsen, Merck, MSD, Sanofi, and Servier, and travel support from Ipsen and Merck. G.C. has been involved in advisory boards and has received remuneration from AAA Pharma, Inc., Ipsen, Keocyt, and Novartis. E.T. has received remuneration from Ipsen, AAA Pharma, and Servier. I.S. has been invited to a medical congress by Ipsen, Biocodex, and Pfizer, and has received a translational research supportive grant from Ipsen. D.G., A.H., and C.M. are employees of Ipsen. A.A. has been involved in advisory boards and has received remuneration from Amgen, AstraZeneca, Bristol Myers Squibb, Ipsen, and Roche, and from Bristol Myers Squibb for being a speaker, and has received travel expenses from AstraZeneca, Bristol Myers Squibb, Novartis, and Pfizer. P.H. has been involved in advisory boards and has received remuneration from AstraZeneca, Erytech, Ipsen, Novartis, Pfizer, and Servier.